The 59-year-old Australian pathologist was remembered Tuesday for revolutionizing melanoma treatment and demonstrating a breathtaking methodological commitment to generating his own survival curves.
SYDNEY — The global scientific establishment paused Tuesday to honor the life, and more specifically the impeccably documented mortality data, of Dr. Richard Scolyer, the 59-year-old Australian pathologist who revolutionized melanoma treatment before rigorously converting his own fatal glioblastoma into a landmark Nature Medicine case study.
Scolyer, who served as co-director of the Melanoma Institute Australia, was diagnosed with a Grade 4 brain tumor last year. Rather than step away from the laboratory, he immediately became the principal investigator, lead author, and sole biological substrate for a world-first neoadjuvant immunotherapy trial, meticulously charting the cellular rebellion inside his own cranium.
It is breathtaking to witness a principal investigator exhibit such profound dedication to the clinical literature that they voluntarily supply the terminal mortality data for their own longitudinal study.
Prior to his death, Scolyer generated unprecedented immunological mapping by applying combination immunotherapy—a protocol he helped pioneer for skin cancer—directly to his own brain tissue prior to surgical resection. To look upon the multi-omic sequencing of his own mutated neuroglial cells, mapped out across the sterile white space of a preprint server, is to witness a man turning the violent betrayal of his biology into a masterpiece of open-access data.
However, as with any novel therapeutic approach, the wider research community has urged rigorous methodological restraint before adopting the self-administered protocol.
While Dr. Scolyer's progression-free survival provides a tantalizing proof-of-concept for neoadjuvant checkpoint inhibition, we must emphasize the limits of extrapolating broad clinical efficacy from an n=1 cohort where the primary funding recipient is also the rat.
Thorne noted that a true randomized controlled trial would have required Scolyer to simultaneously develop a second, placebo-controlled brain tumor to properly isolate the treatment variables, a biological feat that even a researcher of his caliber was unable to synthesize before systemic failure.
Scolyer's final observations, including a perfectly plotted Kaplan-Meier survival curve ending exactly at his own time of death, will be published in The New England Journal of Medicine pending standard peer review by living scientists.